Sol Gel Technologies Ltd Receivables Turnover Ratio (SLGL), from the fourth quarter 2025 to the fourth quarter 2024 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Sol gel Technologies Ltd   (NASDAQ: SLGL)
 

Sol Gel Technologies Ltd Accounts Receivables Turnover Ratio from the fourth quarter 2025 to the fourth quarter 2024

Quarterly Results, Trends, Rankings, Statistics


Sol Gel Technologies Ltd 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 9.19, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Sol Gel Technologies Ltd in Dec 31 2025 quarter, has decreased to 40 days, compared to 56 days, in the 0 quarter.

If we take a look into Healthcare sector 131 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1333, from overall ranking in the third quarter 2025 at 2704.

What is Receivable Turnover Ratio?
What is Sol Gel Technologies Ltd Selling?


What is Receivable Turnover Ratio?





SLGL Receivables Turnover Ratio (Dec 31 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2024)
IV. Quarter
Y / Y Receivable Change -45.26 % -45.26 % 65.7 % -45.26 % 853.58 %
Y / Y Revenue Change 68.04 % - 217.71 % - 642.47 %
Receivable Turnover Ratio (TTM) 9.19 6.56 6 4.46 4.03
SLGL's Total Ranking # 1333 # 2704 # # #
Accounts Receivable average collection period days 40 56 61 82 91
Seq. Receivable Change 0 % -80.4 % 410.16 % -45.26 % 0 %
Seq. Revenue Change - - - - -


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 132
Overall Market # 1333

Receivable Turnover Ratio Statistics
High Average Low
9.85 4.01 0.49
(Dec 31 2025)   (Dec 31 2022)






Financial Statements
Sol Gel Technologies Ltd 's Accounts Receivable $ 2 Millions Visit SLGL's Balance sheet
Sol Gel Technologies Ltd 's Sales TTM $ 37 Millions Visit SLGL's Income Statement
Sources of SLGL's Revenues Visit SLGL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SLGL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SLGL's Growth Rates SLGL's Roa SLGL's Inventory Turnover Ratio SLGL's Dividend Comparisons
SLGL's Profitability Ratios SLGL's Roi SLGL's Asset Turnover Ratio SLGL's Dividend Growth
SLGL's Valuation Ratios SLGL's Roe SLGL's Financial Strength Ratios SLGL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2025 Receivable at quarter ending Dec 31 2025
Eyepoint Inc   45.42 $ 31.371  Millions$ 0.691  Millions
X4 Pharmaceuticals Inc  45.05 $ 35.113  Millions$ 0.780  Millions
Fortrea Holdings Inc   44.55 $ 2,723.400  Millions$ 61.125  Millions
Longduoduo Co Ltd  44.55 $ 2.722  Millions$ 0.061  Millions
Lifevantage Corp  44.29 $ 208.401  Millions$ 4.705  Millions
Valion Bio Inc   42.84 $ 0.482  Millions$ 0.011  Millions
Kyntra Bio Inc   41.55 $ 6.440  Millions$ 0.155  Millions
Cytomx Therapeutics Inc   40.82 $ 76.201  Millions$ 1.867  Millions
Solana Company  40.38 $ 6.017  Millions$ 0.149  Millions
Atara Biotherapeutics Inc   40.31 $ 121.355  Millions$ 3.010  Millions
Nature s Sunshine Products inc   39.85 $ 479.724  Millions$ 12.040  Millions
National Vision Holdings Inc   39.24 $ 1,987.488  Millions$ 50.646  Millions
Lineage Cell Therapeutics Inc   39.16 $ 14.556  Millions$ 0.372  Millions
Monte Rosa Therapeutics Inc   37.07 $ 123.672  Millions$ 3.336  Millions
Meiragtx Holdings Plc  36.74 $ 81.391  Millions$ 2.215  Millions
Protagonist Therapeutics inc   35.26 $ 46.016  Millions$ 1.305  Millions
Stoke Therapeutics Inc   35.18 $ 184.420  Millions$ 5.243  Millions
Agenus Inc  32.27 $ 114.196  Millions$ 3.539  Millions
Metagenomi Therapeutics Inc   32.01 $ 25.210  Millions$ 0.788  Millions
U S Physical Therapy Inc  30.83 $ 780.990  Millions$ 25.331  Millions
Invo Fertility Inc   30.16 $ 6.841  Millions$ 0.227  Millions
Innovative Eyewear Inc   28.53 $ 2.662  Millions$ 0.093  Millions
Aesthetic Medical International Holdings Group Limited  28.50 $ 106.636  Millions$ 3.742  Millions
Puretech Health Plc  28.24 $ 4.659  Millions$ 0.165  Millions
Newgenivf Group Limited  27.02 $ 4.726  Millions$ 0.175  Millions
Evotec Se  26.89 $ 882.978  Millions$ 32.835  Millions
Electrocore Inc   26.63 $ 31.800  Millions$ 1.194  Millions
Innovage Holding Corp   26.44 $ 915.371  Millions$ 34.626  Millions
Premier Air Charter Holdings Inc   26.15 $ 31.878  Millions$ 1.219  Millions
Telix Pharmaceuticals Ltd  26.01 $ 803.438  Millions$ 30.889  Millions

Date modified: 2026-07-07T13:17:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.